Zydus Cadila, an innovative global pharmaceutical company, has received the final approval from US Food Drug and Administrator (USFDA) to market Pioglitazone HC1 tablets in different strengths of 15mg, 30mg and 45mg. The drug falls in the anti-diabetics segment.
The estimated sales in 2012 as per IMS for Pioglitazone HC1 tablets was $2 billion. Further, the group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.
Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |